These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 36483622)
21. Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study). He M; Yan W; Zhang Y; Kong Y; Han X; Ren J; Zhao Z; Liu G; Shi J; Li Y Platelets; 2022 Nov; 33(8):1146-1152. PubMed ID: 35379064 [TBL] [Abstract][Full Text] [Related]
22. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. Liu Z; Tian R; Wang Y; Chen Q; Li J; Xu L; Zhang S Thromb Haemost; 2020 Aug; 120(8):1221-1229. PubMed ID: 32668483 [TBL] [Abstract][Full Text] [Related]
23. Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Ortega-Paz L; Franchi F; Rollini F; Galli M; Been L; Ghanem G; Shalhoub A; Ossi T; Rivas A; Zhou X; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Jennings LK; Angiolillo DJ Thromb Haemost; 2024 Mar; 124(3):263-273. PubMed ID: 37224883 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060 [TBL] [Abstract][Full Text] [Related]
25. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Hauguel-Moreau M; Boccara F; Boyd A; Salem JE; Brugier D; Curjol A; Hulot JS; Kerneis M; Galier S; Cohen A; Montalescot G; Collet JP; Silvain J Eur Heart J; 2017 Jun; 38(21):1676-1686. PubMed ID: 28065907 [TBL] [Abstract][Full Text] [Related]
26. Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Zafar MU; Baber U; Smith DA; Sartori S; Contreras J; Rey-Mendoza J; Linares-Koloffon CA; Escolar G; Mehran R; Fuster V; Badimon JJ Thromb Haemost; 2017 Oct; 117(10):1981-1988. PubMed ID: 28837213 [TBL] [Abstract][Full Text] [Related]
27. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. Galli M; Franchi F; Rollini F; Been L; Jaoude PA; Rivas A; Zhou X; Jia S; Maaliki N; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Geisler T; Jennings LK; Bass TA; Angiolillo DJ Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):728-737. PubMed ID: 35353154 [TBL] [Abstract][Full Text] [Related]
28. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis. Selhorst G; Schmidtler F; Ott A; Hitzke E; Tomelden J; Antoni D; Hoffmann E; Rieber J Platelets; 2019; 30(3):341-347. PubMed ID: 29521570 [TBL] [Abstract][Full Text] [Related]
29. Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study. Chyrchel B; Kruszelnicka O; Surdacki A Cardiovasc Diabetol; 2022 Nov; 21(1):249. PubMed ID: 36397167 [TBL] [Abstract][Full Text] [Related]
30. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522 [TBL] [Abstract][Full Text] [Related]
31. Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume. Zhang Y; Peng R; Li X; Cheng G; Wang X; Yu J; Hua M; Chen X; Zhou Z Thromb J; 2021 Dec; 19(1):97. PubMed ID: 34876147 [TBL] [Abstract][Full Text] [Related]
32. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884 [TBL] [Abstract][Full Text] [Related]
33. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638 [TBL] [Abstract][Full Text] [Related]
34. Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. Gaglia MA; Lipinski MJ; Lhermusier T; Steinvil A; Kiramijyan S; Pokharel S; Torguson R; Angiolillo DJ; Wallentin L; Storey RF; Waksman R Am J Cardiol; 2017 Apr; 119(8):1135-1140. PubMed ID: 28202132 [TBL] [Abstract][Full Text] [Related]
35. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310 [TBL] [Abstract][Full Text] [Related]
37. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. He M; Liu B; Sun D; Pan Y; Zheng W; Shi J; Zhao S; Dong X; Lu S; Li M; Han Y; Li Y Int J Cardiol; 2016 Jul; 215():209-13. PubMed ID: 27128532 [TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624 [TBL] [Abstract][Full Text] [Related]
39. Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china. Peng W; Zhang Y; Lin Y Front Cardiovasc Med; 2022; 9():937261. PubMed ID: 35958420 [TBL] [Abstract][Full Text] [Related]
40. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Franchi F; James SK; Ghukasyan Lakic T; Budaj AJ; Cornel JH; Katus HA; Keltai M; Kontny F; Lewis BS; Storey RF; Himmelmann A; Wallentin L; Angiolillo DJ; J Am Heart Assoc; 2019 Mar; 8(6):e011139. PubMed ID: 30857464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]